# Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

> **NCT03254511** · PHASE2 · UNKNOWN · sponsor: **Mashhad University of Medical Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Esophageal Neoplasms

## Interventions

- **DRUG:** Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
- **RADIATION:** Radiotherapy
- **DRUG:** Chemotherapeutic Combinations

## Key facts

- **NCT ID:** NCT03254511
- **Lead sponsor:** Mashhad University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07-22
- **Primary completion:** 2017-12-30
- **Final completion:** 2018-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254511, "Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03254511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*